Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy – Endpoints News
Endpoints News |
Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy
Endpoints News Solid Biosciences has come up with a $50 million crossover round that would appear to be positioning the company for an IPO as it advances a gene therapy for Duchenne muscular dystrophy into the clinic. Founded by Duchenne dad — and former JP … Biogen-backed Duchenne firm Solid Biosciences raises $50M Solid Biosciences Raises up to $50 Million in Series C Financing … |
